Shares in psychedelic medicine companies are unlikely to swing up or down by more than 30% in a sustained way through the third quarter of 2026. The optimistic story about these drugs changing mental healthcare is already reflected in current stock prices. Only a major event — like a big clinical trial result or one company buying another — would move the needle significantly, and neither looks imminent.
Consensus of three agents (investor, fda_reviewer, journalist). Current price drift indicates the therapeutic narrative is fully priced; only binary de-risking events move institutional capital, and none are dated in current signals.